Burns, Trauma and Critical Care Research Centre, The University of Queensland, Royal Brisbane and Women's Hospital, Brisbane, Queensland, Australia.
BMC Anesthesiol. 2011 Feb 20;11:3. doi: 10.1186/1471-2253-11-3.
Critical illness, mediated by trauma or sepsis, can lead to physiological changes that alter the pharmacokinetics of antibiotics and may result in sub-therapeutic concentrations at the sites of infection. The first aim of this project is to identify the clinical characteristics of critically ill patients with significant trauma that have been recently admitted to ICU that may predict the dosing requirements for the antibiotic, cefazolin. The second aim of this is to identify the clinical characteristics of critically ill patients with sepsis that may predict the dosing requirements for the combination antibiotic, piperacillin-tazobactam.
METHODS/DESIGN: This is an observational pharmacokinetic study of patients with trauma (cefazolin) or with sepsis (piperacillin-tazobactam). Participants will have samples from blood and urine, collected at different intervals. Patients will also have a microdialysis catheter inserted into subcutaneous tissue to measure interstitial fluid penetration of the antibiotic. Participants will be administered sinistrin, indocyanine green and sodium bromide as well as have cardiac output monitoring performed and tetrapolar bioimpedance to determine physiological changes resulting from pathology. Analysis of samples will be performed using validated liquid chromatography tandem mass-spectrometry. Pharmacokinetic analysis will be performed using non-linear mixed effects modeling to determine individual and population pharmacokinetic parameters of antibiotics.
The study will describe cefazolin and piperacillin-tazobactam concentrations in plasma and the interstitial fluid of tissues in trauma and sepsis patients respectively. The results of this study will guide clinicians to effectively dose these antibiotics in order to maximize the concentration of antibiotics in the interstitial fluid of tissues.
创伤或脓毒症引起的危重病可导致改变抗生素药代动力学的生理变化,并可能导致感染部位的治疗浓度不足。本项目的第一个目的是确定最近入住 ICU 的严重创伤患者的临床特征,这些特征可能预测抗生素头孢唑林的剂量需求。本项目的第二个目的是确定患有脓毒症的危重病患者的临床特征,这些特征可能预测联合抗生素哌拉西林-他唑巴坦的剂量需求。
方法/设计:这是一项关于创伤(头孢唑林)或脓毒症(哌拉西林-他唑巴坦)患者的观察性药代动力学研究。参与者将在不同时间间隔采集血液和尿液样本。患者还将在皮下组织中插入微透析导管,以测量抗生素的间质液渗透。参与者将接受辛替斯汀、吲哚菁绿和溴化钠给药,并进行心输出量监测和四极生物电阻抗测量,以确定病理引起的生理变化。使用经过验证的液相色谱串联质谱法分析样品。使用非线性混合效应模型进行药代动力学分析,以确定抗生素的个体和群体药代动力学参数。
该研究将描述头孢唑林和哌拉西林-他唑巴坦在创伤和脓毒症患者的血浆和组织间质液中的浓度。本研究的结果将指导临床医生有效地给予这些抗生素,以最大限度地提高组织间质液中抗生素的浓度。